Lv4
480 积分 2025-09-29 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2天前
已完结
PL02.06: Primary Results from Phase 3 EVOKE-03/KEYNOTE D46: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC
2天前
求助中
PL02.04: Risvutatug Rezetecan (a B7-H3-Directed ADC) Versus Topotecan in Relapsed SCLC: Primary Results of Phase 3 ARTEMIS-008
2天前
已完结
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
2天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
2天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
6天前
已完结
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
6天前
已完结
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
10天前
已完结
The next generation of antibody–drug conjugates
1个月前
已完结
皖公网安备34019202002308
